5.51 -0.03 (-0.60%)
After hours: 4:11PM EDT
|Bid||5.20 x 3100|
|Ask||5.67 x 3000|
|Day's Range||5.40 - 5.64|
|52 Week Range||3.64 - 6.43|
|Beta (3Y Monthly)||2.11|
|PE Ratio (TTM)||N/A|
|Earnings Date||May 8, 2018 - May 14, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||10.67|
Inovio Pharmaceuticals, Inc. (INO) announced today that it has received the first two U.S. patents for its DNA-encoded monoclonal antibody technology (dMAb™) from the U.S. Patent & Trademark Office and has been awarded a $2.2 million grant from the Bill & Melinda Gates Foundation to advance its dMAb platform and new clinical delivery devices. This U.S. patent protection of Inovio’s dMAb intellectual property will provide exclusivity for the use of this innovative technology.
Inovio Pharmaceuticals, Inc. (INO) announced today that its Ebola vaccine (INO-4212) provided 100% protection following a challenge with a lethal dose of the Ebola virus in a preclinical study. Scientists observed that vaccination induced long-term immune responses in monkeys that were detectable for at least one year after the final vaccination. Laurent Humeau, Ph.D., Inovio’s Senior Vice President R&D, said, “Unlike all other Ebola vaccine candidates in development, INO-4212 is a vaccine that has shown to be stable at room temperature for one year.
NEW YORK, Oct. 09, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Inovio Pharmaceuticals, Inc. (INO) announced today the successful animal testing of DNA-encoded monoclonal antibodies targeting the immune checkpoint molecule CTLA-4 as published in Cancer Research. More importantly, Inovio’s dMAb constructs for anti-human CTLA-4 antibodies ipilimumab (YERVOY®) and tremelimumab, achieved high expression levels in mice (approximately 85µg/ml and 58µg/ml, respectively). This research publication is significant because it is the first to report on the use of Inovio dMAb technology to develop novel monoclonal antibody-based therapies targeting checkpoint inhibitors.
Vaxart's (VXRT) oral flu vaccine candidate achieves 39% reduction in flu illness compared to 27% for market leader, Sanofi's Fluzone.
NEW YORK, NY / ACCESSWIRE / October 3, 2018 / Inovio Pharmaceuticals saw its shares climb over 14% by the close on Tuesday as traders digested positive data that was published in Clinical Cancer Research. ...
Inovio Pharmaceuticals, Inc. (INO) announced today a paper published in a major cancer journal detailed results of a patient with head and neck cancer treated with MEDI0457 achieved a sustained complete response (full remission) on treatment with a subsequent PD-1 checkpoint inhibitor. In the Inovio-sponsored study of 22 patients with head and neck squamous cell carcinoma the company reported 91% (20/22) showed T cell activity in the blood or tissue. MEDI0457 – formerly called INO-3112 – was in 2015 licensed to MedImmune, the global biologics research and development arm of AstraZeneca. Dr. J. Joseph Kim, Inovio's President and CEO, said, "We are buoyed by the study as it lends support to all of our HPV and oncology programs.
After ending almost flat in the week ended Sept. 14, biotech stocks have seen some bounce in the running week, with the iShares NASDAQ Biotechnology Index (NASDAQ: IBB ) up about 1.3 percent through Thursday. ...
HENDERSON, NV / ACCESSWIRE / September 18, 2018 / We have discovered a very interesting biotechnology company ENDV (Endonovo Therapeutics, Inc.), has an FDA cleared product, and is flying under the radar. ...
Inovio Pharmaceuticals, Inc. (INO) announced today that its SynCon® vaccine approach using a collection of DNA antigens generated broadly protective antibody responses against the most deadly strains of the H3N2 influenza viruses from the past 50 years and provided complete protection against heterologous lethal challenge in a preclinical study. Study results were published online in the journal, Human Gene Therapy, in an article by Inovio and its collaborators entitled, “A Synthetic Micro-Consensus DNA Vaccine Generates Comprehensive Influenza-A H3N2 Immunity and Protects Mice Against Lethal Challenge by Multiple H3N2 Viruses.” This work was supported by a grant from the U.S. National Institutes of Health.
Biotech were trending mostly sideways in the week ending Sept. 14 after posting weekly gains in the previous two weeks. Notwithstanding the overall muted sentiment, there was some activity in reaction ...
Inovio (INO) focuses on the development of its most advanced candidate, VGX-3100 vaccine, which has been progressing well. Its collaboration with big pharma companies exhibits strong growth.
Anyone researching Inovio Pharmaceuticals Inc (NASDAQ:INO) might want to consider the historical volatility of the share price. Modern finance theory considers volatility to be a measure of risk, and thereRead More...
Inovio Pharmaceuticals (INO) administers dosage in the first patient under a phase I/IIa trial to assess its MERS vaccine INO-4700.
Inovio Pharmaceuticals, Inc. (INO) announced today announced the dosing of the first subject with its vaccine to prevent infection from the deadly MERS virus (Middle East Respiratory Syndrome) in a Phase 1/2a study to evaluate INO-4700 (or GLS-5300). The trial is ongoing in South Korea sponsored by Inovio’s Korean development partner for its MERS vaccine, GeneOne Life Science (011000.KS).
Inovio Pharmaceuticals (INO) and Korean partner GeneOne Life Science dose the first patient in a phase I study, which will assess its hepatitis C vaccine GLS-6150.
Inovio Pharmaceuticals, Inc. (INO) and GeneOne Life Science (011000.KS) today announced they have dosed the first patient in a Phase 1 study designed to evaluate a preventive vaccine against hepatitis C infection. Recruitment has already begun in South Korea, where GeneOne is responsible for conducting and funding this Phase 1 trial to assess the ability of Inovio’s hepatitis C vaccine (GLS-6150) to boost immunity in people who have been treated and cleared of the virus. Pending study results, Inovio’s vaccine could be employed to prevent infection and re-infection.
NEW YORK, NY / ACCESSWIRE / August 23, 2018 / U.S. markets were mixed on Wednesday, with the Dow Jones and S&P 500 finishing in the red, as the Federal Reserve meeting indicated another interest rate hike ...
PLYMOUTH MEETING, Pa., Aug. 21, 2018-- Inovio Pharmaceuticals, Inc. today announced that the Company will participate in the following upcoming investment conferences:. Rodman and Renshaw 20 th Annual ...
Inovio Pharmaceuticals (INO) doses the first patient in a phase I/II study, which will evaluate its HIV vaccine Pennvax-GP's ability to bring about remission of HIV.
Inovio Pharmaceuticals, Inc. (INO) today announced that it has dosed its first patient in a Phase 1/2a study designed to evaluate the safety, immunogenicity and clinical efficacy of INO-5401, Inovio’s novel cancer immunotherapy that encodes multiple cancer antigens, plus INO-9012, a T cell activator, in combination with atezolizumab, (F. Hoffman-La Roche Ltd.) a PD-L1 inhibitor, for the treatment of advanced or metastatic bladder cancer. The trial, which is being managed by Inovio, is expected to enroll approximately 85 patients at sites located in the United States and Spain. Dr. J. Joseph Kim, Inovio's President and Chief Executive Officer, said, “We are very encouraged to dose our first patient with the aspiration that we can demonstrate the immense potential of our INO-5401 immunotherapy to treat advanced bladder patients as well as those with other cancers.